ESR1 peptides vaccine study (Breast Cancer)

What is the Purpose of this Study?

If you choose to join this study you will:
-Get the study vaccine (ESR1 peptide)
-Return to the Duke Cancer Center for follow-up visits 6-8 times over 10 weeks.
-Be contacted by phone every 12 weeks to see how you are doing
-Have a skin biopsy (piece of skin will be taken) where the study vaccine was injected.
What is the Condition Being Studied?
Breast Cancer

Who Can Participate in this Study?

-Adults who:

--Are diagnosed with breast cancer

--Have completed chemotherapy or surgery.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to find out if a new vaccine (ESR1 peptides) is safe and if they will help people with Estrogen receptor positive (ER+) breast cancer.

Study Details

Full Title
A Phase I Study of Cancer Peptides plus GM-CSF and Adjuvant Following Completion of Prescribed Systemic Therapy of Estrogen Receptor Positive Breast Cancer
Principal Investigator
Herbert Lyerly
George Barth Geller Distinguished Professor of Immunology

Contacts
Protocol Number
IRB:
PRO00104868

NCT:
NCT04270149
ClinicalTrials.gov
View on ClinicalTrials.gov